Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection

E. Gane*, Z. Ben Ari, L. Mollison, E. Zuckerman, R. Bruck, Y. Baruch, A. Y.M. Howe, J. Wahl, S. Bhanja, P. Hwang, Y. Zhao, M. N. Robertson

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology